Bromazepam

證據等級: L5

預測適應症: 1 個

Bromazepam: From Anxiety Disorders to Migraine Disorder

One-Sentence Summary

Bromazepam is a 1,4-benzodiazepine, primarily used for anxiety and sedation. The TxGNN model predicts it may be effective for Migraine Disorder (rank #12,910), however the sole identified clinical trial represents a negative signal — bromazepam appears as a drug being withdrawn in a medication overuse headache (MOH) study, not as a therapeutic agent. There is 0 supportive literature for this repurposing direction.

Quick Overview

Item	Content
Original Indication	Anxiety disorders (benzodiazepine class; no local authorization on file)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.06%
Evidence Level	L5
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Bromazepam belongs to the 1,4-benzodiazepine class. It acts as a positive allosteric modulator of GABA-A receptors, enhancing GABAergic inhibitory neurotransmission. In theory, augmenting GABA-mediated inhibition could modulate trigeminal nociceptive pathways involved in migraine pathophysiology — this is the mechanistic basis on which the TxGNN model likely assigns a high prediction score.

However, the theoretical mechanistic link does not translate into a plausible therapeutic relationship in this case. Benzodiazepines — including bromazepam — are among the highest-risk drug classes for inducing medication overuse headache (MOH), a debilitating secondary headache disorder that affects approximately 2% of migraine patients. Chronic benzodiazepine use can paradoxically worsen headache frequency and severity, creating a cycle of dependency and rebound headache. The mechanistic link here is adverse rather than therapeutic.

Crucially, the only clinical trial retrieved in the evidence search (NCT04410536) investigates a home-withdrawal program for MOH patients — a context in which bromazepam is plausibly one of the drugs being withdrawn, not the intervention being tested. This represents an inverted evidence signal: existing clinical research activity around bromazepam and headache disorders points toward harm reduction, not therapeutic repurposing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04410536	Phase 4	Completed	25	⚠️ Adverse signal — Home-withdrawal program combined with behavioural therapy for medication overuse headache (MOH) during COVID-19. Bromazepam's likely role is as one of the overused drugs being withdrawn, not as the therapeutic agent. This trial does not support repurposing; it is evidence of harm potential.

Literature Evidence

Currently no related literature available.

Saudi Arabia Market Information

Bromazepam has no registered authorizations in Saudi Arabia. No license data to display.

Safety Considerations

Detailed safety data (package insert warnings, contraindications) were not available in this evidence pack. Based on drug class knowledge, the following class-level considerations apply:

Benzodiazepine class risks: dependence, tolerance, withdrawal syndrome, CNS depression, respiratory depression in combination with opioids or alcohol
Specific relevance to migraine: chronic use is a well-established risk factor for medication overuse headache (MOH) — this is a contraindication to repurposing, not a manageable side effect
Elderly population: falls, cognitive impairment, and paradoxical agitation are known risks

Please refer to the package insert for complete safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high prediction score, but the mechanistic basis is counterproductive — benzodiazepines including bromazepam are a recognised cause of medication overuse headache, the opposite of the intended therapeutic effect. The single identified clinical trial reinforces this concern. With zero supportive literature, zero Saudi Arabia authorizations, and an adverse mechanistic profile in the target indication, this candidate does not meet the threshold for further development.

To proceed, the following would be needed:

A credible mechanistic hypothesis that separates GABA-A modulation from MOH induction risk (e.g., evidence that short-term or specific dosing regimens avoid headache chronification)
At least one positive clinical signal — a prospective study or case series showing bromazepam reducing migraine frequency, not causing rebound headache
Full MOA data from DrugBank to identify any off-target effects (e.g., calcium channel modulation) that might independently support migraine prophylaxis
Re-evaluation of the TxGNN training data to determine whether the migraine prediction is driven by co-occurrence in headache-disorder patient records (confounding) rather than a true therapeutic signal
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.